Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril

Alcocer, Luis; Campos, C.; Bahena, Judith Huerta; Nacaud, A.; Carillo, J. Parra; Calvo, C.; Weber, Christian; Lerebours, Guy; Mickalonis, L.; Villahermosa, M. T.

doi:10.1007/bf00879032

Cited by 9 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ACE inhibitors have been demonstrated to lower blood pressure in hypertensive patients (7). Within the group of ACE inhibitors, enalapril is an effective and safe drug (8), and is one of the most widely prescribed drugs of its class.…”

Section: Introductionmentioning

confidence: 99%

Clinical efficacy and safety of telmisartan 80 mg once daily compared with enalapril 20 mg once daily in patients with mild-to-moderate hypertension: results of a multicentre study

Alcocer

Fernández-Bonetti

Campos

et al. 2004

International Journal of Clinical Practice

Self Cite

View full text Add to dashboard Cite

The efficacy and safety of once-daily telmisartan 80 mg vs. once-daily enalapril 20 mg in the treatment of essential hypertension were evaluated in a multicentre, singleblind, placebo-controlled, randomised trial. In total, 68 patients (49 females, 19 males) with mild-to-moderate hypertension, defined as morning supine systolic blood pressure (SBP) 141-149 mmHg, diastolic blood pressure (DBP) 95-114 mmHg, were enrolled. After a 4-week placebo run-in phase, patients were randomly assigned to treatment with telmisartan or enalapril administered once daily in the morning for 8 weeks. No statistically significant differences were found in the baseline characteristics of patients in either group. Both SBP and DBP were decreased in both treatment groups, but the reductions were statistically different in favour of telmisartan (SBP, p ¼ 0.013; DBP, p ¼ 0.002). The incidence of adverse effects was lower in the telmisartan group, with the absence of cough. In conclusion, telmisartan is more effective and better tolerated than enalapril for the treatment of hypertension and has the advantage that it does not cause cough.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical efficacy and safety of telmisartan 80 mg once daily compared with enalapril 20 mg once daily in patients with mild-to-moderate hypertension: results of a multicentre study

Alcocer

Fernández-Bonetti

Campos

et al. 2004

International Journal of Clinical Practice

Self Cite

View full text Add to dashboard Cite

show abstract

Class effects and evidence-based medicine

Furberg

2000

Clin Cardiol

View full text Add to dashboard Cite

Drugs grouped into a therapeutic class on the basis of a common mechanism of action often have considerably different pharmacodynamic and pharmacokinetic properties. Among angiotensin-converting enzyme (ACE) inhibitors, differences with potential clinical relevance include potency, whether the drug is an active compound or requires metabolic activation, lipophilicity, route(s) of elimination, and half-life. Large clinical trials have documented the clinical benefits of several ACE inhibitors in various patient populations, and many clinical effects of ACE inhibitors are likely to be the same. However, there are possible quantitative differences among ACE inhibitors that may alter the overall therapeutic benefits for specific patient populations and indications. Equipotency in terms of clinical efficacy is difficult to determine. Since the concept of ''class effect" is a term of convenience that has no universally accepted definition and subsequently should not form the basis for the practice of evidence-based medicine, untested drugs of a "class" should be considered to be unproven drugs.

show abstract